Dr. Charles (Chaz) Hong is an Associate Professor of Cardiovascular Medicine at Vanderbilt University School of Medicine, where he is a Co-Director of Center for Inherited Heart Disease, and a member of the Vanderbilt Institute of Chemical Biology and the Vanderbilt Center for Stem Cell Biology. His research is focused on chemical biology of vertebrate development and stem cell differentiation. He received his MD and PhD from Yale, and did cardiology fellowship at Massachusetts General Hospital. His honors include election to American Society for Clinical Research, Sarnoff Scholar Award, GlaxoSmithKline Young Investigator Award and Finalist for AHA Irvin H. Page Young Investigator Award.
The goal of the Hong lab, a part of the Vanderbilt Institute of Chemical Biology, is to discover and characterize small molecules that promote cardiac differentiation in pluripotent stem cells and heart repair in vivo. We also have an active medicinal chemistry program to develop optimized small molecules ultimately for future regenerative therapies.
Dr. Hong’s research centers around chemical biology of vertebrate development. His lab uses small molecules discovered in high-throughput screens (HTS) as chemical tools to dissect fundamental events in early embryogenesis such as body axis formation. Another important goal of his research is to develop small molecule reagents to harness the discovery and therapeutic potentials of stem cells. Dr. Hong discovered dorsomorphin, the first small molecule BMP (bone morphogenetic protein) signal inhibitor, which has been successfully used to promote both neural and cardiac differentiation in various stem cell models. In addition, his lab has discovered subtype-selective BMP inhibitors, and exquisitely selective modulators of Wnt, Notch and Hedgehog pathways. Since aberrant activities of developmental pathways play major roles in pathogenesis of many adult diseases, we are exploring therapeutic potential of our novel small molecules for a number of diseases. For example, the Hong lab has made key contributions to the elucidation of BMP signaling as a promising therapeutic target for anemia of chronic disease, heterotopic ossification syndromes, inflammatory bowel disease, and atherosclerosis.
Copyright ©2013 NHLBI Progenitor Cell Biology Consortium.